Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, Tsuchihashi K, Suina K, Maeda Y, Saya H, Ohtsu A.
Shitara K, et al. Among authors: maeda y.
Gastric Cancer. 2017 Nov;20(6):1004-1009. doi: 10.1007/s10120-017-0720-y. Epub 2017 May 2.
Gastric Cancer. 2017.
PMID: 28466360
Clinical Trial.